Published in J Infect Dis on April 30, 2004
Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults. PLoS One (2010) 0.88
Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1. Clin Vaccine Immunol (2006) 0.78
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. J Infect Dis (2016) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Naturally acquired simian retrovirus infections in central African hunters. Lancet (2004) 5.34
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med (2003) 4.69
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods (2002) 4.48
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83
The World Health Organization African region laboratory accreditation process: improving the quality of laboratory systems in the African region. Am J Clin Pathol (2010) 3.83
Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One (2012) 3.69
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Host determinants of HIV-1 control in African Americans. J Infect Dis (2010) 2.90
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci U S A (2005) 2.86
Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis (2011) 2.86
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 2.68
Policy rebuttal. HIV vaccine trial justified. Science (2004) 2.49
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology (2008) 2.37
Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants. AIDS (2002) 1.98
Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya. PLoS One (2008) 1.97
Detection of HIV-1 subtypes, recombinants, and dual infections in east Africa by a multi-region hybridization assay. AIDS (2002) 1.96
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine (2005) 1.96
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med (2002) 1.93
Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology (2008) 1.89
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine (2011) 1.88
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med (2014) 1.87
Prevalences, genotypes, and risk factors for HIV transmission in South America. J Acquir Immune Defic Syndr (2005) 1.82
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS (2003) 1.81
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis (2010) 1.79
HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS (2010) 1.76
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 1.75
CCL3L1 and HIV/AIDS susceptibility. Nat Med (2009) 1.73
Impact of persistent HIV replication on CD4 negative Vγ2Vδ2 T cells. J Infect Dis (2012) 1.70
Identification of CRF34_01B, a second circulating recombinant form unrelated to and more complex than CRF15_01B, among injecting drug users in northern Thailand. AIDS Res Hum Retroviruses (2007) 1.69
Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol (2003) 1.66
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One (2013) 1.65
Vaccine protection against Zika virus from Brazil. Nature (2016) 1.65
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis (2012) 1.65
A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand. AIDS Res Hum Retroviruses (2003) 1.64
Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials. PLoS One (2008) 1.55
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis (2011) 1.55
Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis (2010) 1.53
Improved renal ischemia tolerance in females influences kidney transplantation outcomes. J Clin Invest (2016) 1.51
Frequency of HIV type 1 dual infection and HIV diversity: analysis of low- and high-risk populations in Mbeya Region, Tanzania. AIDS Res Hum Retroviruses (2006) 1.50
Outbreak of a West African recombinant of HIV-1 in Tashkent, Uzbekistan. J Acquir Immune Defic Syndr (2005) 1.49
A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine. Antivir Ther (2012) 1.48
Large-scale human immunodeficiency virus rapid test evaluation in a low-prevalence ugandan blood bank population. J Clin Microbiol (2007) 1.47
Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate. AIDS Res Hum Retroviruses (2002) 1.46
When Do DCD Donors Die?: Outcomes and Implications of DCD at a High-volume, Single-center OPO in the United States. Ann Surg (2016) 1.42
Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis (2008) 1.42
Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A (2009) 1.41
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One (2010) 1.41
Oral preexposure prophylaxis for HIV--another arrow in the quiver? N Engl J Med (2010) 1.40
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr (2007) 1.39
HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS (2007) 1.38
Exposure to nonhuman primates in rural Cameroon. Emerg Infect Dis (2004) 1.35
Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr (2009) 1.34
Higher HIV-1 incidence and genetic complexity along main roads in Rakai District, Uganda. J Acquir Immune Defic Syndr (2006) 1.34
HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr (2002) 1.33
Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis (2003) 1.33
Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology (2008) 1.32
Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines (2010) 1.31